Literature DB >> 25202066

Characterization of non-alcoholic steatohepatitis-derived hepatocellular carcinoma as a human stratification model in mice.

Kazuki Takakura1, Shigeo Koido1, Masato Fujii2, Taishi Hashiguchi2, Yuichiro Shibazaki2, Hiroyuki Yoneyama2, Hiroaki Katagi3, Mikio Kajihara4, Takeyuki Misawa5, Sadamu Homma6, Toshifumi Ohkusa4, Hisao Tajiri7.   

Abstract

The therapeutic strategy against hepatocellular carcinoma (HCC) is determined by tumor stage and liver function. Improvements of stratification contribute to extending the survival of patients. However, stratification has been attributed little attention in animal models largely due to the lack of suitable models. Herein we showed that the recently-reported, non-alcoholic steatohepatitis-derived HCC model (STAM model) is the first murine model in which the concept of human stratification is applicable by demonstrating the following features: (i) at least 4 detectable tumor nodules; (ii) average tumor growth rate of 150 % from 16 to 20 weeks of age; (iii) no visible metastasis; and (iv) relatively preserved liver function. These observations suggested that HCC in STAM mice is equivalent to stages B to C of the Barcelona Clinic Liver Cancer (BCLC) staging system for humans. Application of the stratification concept to experimental animals will create new avenues to establish pharmacological intervention against HCC. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Barcelona Clinic Liver Cancer staging system; Child-Pugh grade; Hepatocellular carcinoma; murine model; non-alcoholic steatohepatitis

Mesh:

Year:  2014        PMID: 25202066

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Design and in vivo activity of A3 adenosine receptor agonist prodrugs.

Authors:  R Rama Suresh; Shanu Jain; Zhoumou Chen; Dilip K Tosh; Yanling Ma; Maren C Podszun; Yaron Rotman; Daniela Salvemini; Kenneth A Jacobson
Journal:  Purinergic Signal       Date:  2020-07-27       Impact factor: 3.765

2.  Tie-ing Up Angiogenesis to Treat Nonalcoholic Steatohepatitis.

Authors:  Nicholas O Davidson
Journal:  Hepatology       Date:  2019-02-08       Impact factor: 17.425

3.  Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.

Authors:  Elizabeth P Newberry; Zoe Hall; Yan Xie; Elizabeth A Molitor; Peter O Bayguinov; Gregory W Strout; James A J Fitzpatrick; Elizabeth M Brunt; Julian L Griffin; Nicholas O Davidson
Journal:  Hepatology       Date:  2021-05-22       Impact factor: 17.298

4.  Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma.

Authors:  Simone Jueliger; John Lyons; Sara Cannito; Illar Pata; Pille Pata; Marianna Shkolnaya; Oriana Lo Re; Marion Peyrou; Francesc Villarroya; Valerio Pazienza; Francesca Rappa; Francesco Cappello; Mohammad Azab; Pietro Taverna; Manlio Vinciguerra
Journal:  Epigenetics       Date:  2016-09-20       Impact factor: 4.528

5.  A novel diet-induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis.

Authors:  Chieko Ejima; Haruna Kuroda; Sonoko Ishizaki
Journal:  Physiol Rep       Date:  2016-11

6.  MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis.

Authors:  Aline de Conti; Juliana Festa Ortega; Volodymyr Tryndyak; Kostiantyn Dreval; Fernando Salvador Moreno; Ivan Rusyn; Frederick A Beland; Igor P Pogribny
Journal:  Oncotarget       Date:  2017-08-01

7.  Inhibition of Cell Proliferation and Growth of Pancreatic Cancer by Silencing of Carbohydrate Sulfotransferase 15 In Vitro and in a Xenograft Model.

Authors:  Kazuki Takakura; Yuichiro Shibazaki; Hiroyuki Yoneyama; Masato Fujii; Taishi Hashiguchi; Zensho Ito; Mikio Kajihara; Takeyuki Misawa; Sadamu Homma; Toshifumi Ohkusa; Shigeo Koido
Journal:  PLoS One       Date:  2015-12-07       Impact factor: 3.240

Review 8.  Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.

Authors:  Jian Wu
Journal:  Oncotarget       Date:  2016-07-05

Review 9.  Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.

Authors:  Kazuki Takakura; Tsunekazu Oikawa; Yoichi Tomita; Yusuke Mizuno; Masanori Nakano; Chisato Saeki; Yuichi Torisu; Masayuki Saruta
Journal:  World J Gastroenterol       Date:  2018-05-14       Impact factor: 5.742

10.  Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.

Authors:  Alexander D Nardo; Nicole G Grün; Maximilian Zeyda; Monika Dumanic; Georg Oberhuber; Elisa Rivelles; Thomas H Helbich; Daniel F Markgraf; Michael Roden; Thierry Claudel; Michael Trauner; Thomas M Stulnig
Journal:  Liver Int       Date:  2020-05-30       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.